The relationship between plasma sCD163/sTWEAK ratio and prognosis in patients with spontaneous acute cerebral hemorrhage

doi:10.11958/20231437

Abstract

Abstract:

Objective To investigate the relationship between the ratio of soluble hemoglobin scavenger receptor 163 protein (sCD163)/soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in plasma and prognosis in patients with spontaneous acute cerebral hemorrhage (ACH). Methods From August 2020 to August 2022, 90 patients with ACH admitted to the Department of Neurosurgery, Harison International Peace Hospital, Hengshui City were regarded as the research group. According to the Glasgow outcome scale, patients with ACH were separated into the poor prognosis group (n=38) and the good prognosis group (n=52). Another 45 healthy examinee who underwent physical examination were used as the control group. Enzyme linked immunosorbent assay (ELISA) was applied to detect plasma sCD163 and sTWEAK levels, and the sCD163/sTWEAK ratio was calculated. Pearson method was applied to analyze the correlation between plasma sCD163, sTWEAK levels, sCD163/sTWEAK ratio and clinical data. Logistic regression was applied to analyze influencing factors of poor prognosis in patients with ACH. Receiver operating characteristic (ROC) was applied to analyze the predictive value of sCD163/sTWEAK ratio for poor prognosis of patients with ACH. Results The plasma levels of sCD163, sTWEAK and sCD163/sTWEAK ratio were obviously higher in the research group than those in the control group (P<0.05). The plasma levels of sCD163, sTWEAK and sCD163/sTWEAK ratio were obviously lower in the good prognosis group than those in the poor prognosis group (P<0.05). Hematoma volume, National Institutes of Health Stroke Scale (NIHSS) scores, hypertension and subtentorial hemorrhage were lower in the good prognosis group than those in the poor prognosis group, and low density lipoprotein cholesterol (LDL-C) was higher in the good prognosis group than that in the poor prognosis group (P<0.05). Correlation analysis showed that plasma sCD163, and sTWEAK levels and the sCD163/sTWEAK ratio were positively correlated with bleeding site, hematoma volume, NIHSS score, white blood cell count, platelet count and neutrophil/lymphocyte ratio (NLR) (P<0.05). Results of Logistic regression analysis showed that sCD163, sTWEAK, sCD163/sTWEAK ratio, hematoma volume, bleeding site and NIHSS score were influencing factors for poor prognosis in patients with ACH (P<0.05). Results of receiver operating characteristic showed that the AUC of sCD163/sTWEAK ratio in evaluating poor prognosis of patients with ACH was 0.850, and the sensitivity and specificity were 86.84% and 69.23%. Conclusion The sCD163/sTWEAK ratio has a high level in the plasma of patients with ACH, which is associated with poor prognosis and has important value in predicting the prognosis of patients with ACH.

Key words: cerebral hemorrhage, cytokine TWEAK, prognosis, soluble hemoglobin scavenger receptor 163 protein, soluble tumor necrosis factor-like weak inducer of apoptosis

CLC Number:

R743.34

Figures/Tables 7

References 21

[1]	张昆龙, 薛白洁, 肖玮, 等. 重复经颅磁刺激对神经病理性疼痛患者疼痛和情绪的影响[J]. 中国现代神经疾病杂志, 2022, 22(11):940-947.
	ZHANG K L, XUE B J, XIAO W, et al. Effects of repetitive transcranial magnetic stimulation on pain and emotion of patients with neuropathic pain[J]. Chin J Contemp Neurol Neurosurg, 2022, 22(11):940-947. doi:10.3969/j.issn.1672-6731.2022.11.005.
[2]	HOSTETTLER I C, SEIFFGE D J, WERRING D J. Intracerebral hemorrhage:an update on diagnosis and treatment[J]. Expert Rev Neurother, 2019, 19(7):679-694. doi:10.1080/14737175.2019.1623671.
[3]	STUHR L K, MADSEN K, JOHANSEN A Z, et al, Combining sCD163 with CA 19-9 increases the predictiveness of pancreatic ductal adenocarcinoma[J]. Cancers (Basel), 2023, 15(3):897. doi:10.3390/cancers15030897.
[4]	NIELSEN M C, HVIDBIERG G R, CLARIA J, et al. Macrophage activation markers,CD163 and CD206,in acute-on-chronic liver failure[J]. Cells, 2020, 9(5):1175. doi:10.3390/cells9051175.
[5]	DA SILVA-CANDAL A, CUSTODIA A, LÓPEZ-DEQUIDT I, et al. sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy[J]. Ann Clin Transl Neurol, 2022, 9(2):171-180. doi:10.1002/acn3.51502.
[6]	SCSÖNBAUER R, LICHTENAUER M, PAAR V, et al. Regular training increases sTWEAK and its decoy receptor sCD163-does training trigger the sTWEAK/sCD163-axis to induce an anti-inflammatory effect?[J]. J Clin Med. 2020, 9(6):1899. doi:10.3390/jcm9061899.
[7]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国脑出血诊治指南(2019)[J]. 中华神经科杂志, 2019, 52(12):994-1005.
	Chinese Medical Association Branch of Neurology,Group of Cerebrovascular diseases, Branch of Neurology,Chinese Medical Association. Chinese Guidelines for Diagnosis and Treatment of cerebral hemorrhage(2019)[J]. Chinese Journal of Neurology, 2019, 52(12):994-1005. doi:10.3760/cma.j.issn.1006-7876.2019.12.003.
[8]	骆金轮, 吴非, 祝东强, 等. 血清HMGB-1 MIF PDGF预测急性脑出血短期预后的临床价值[J]. 河北医学, 2021, 27(5):785-789.
	LUO J L, WU F, ZHU D Q, et al. Clinical value of serum HMGB-1 MIF PDGF in predicting short-term prognosis of acute cerebral hemorrhage[J]. Journal of Hebei Medical Sciences, 2019, 27(5):785-789. doi:10.3969/j.issn.1006-6233.2021.05.018.
[9]	LATTANZI S, BRIGO F, TRINKA E, et al. Neutrophil-to-lymphocyte ratio in acute cerebral hemorrhage:a system review[J]. Transl Stroke Res, 2019, 10(2):137-145. doi:10.1007/s12975-018-0649-4.
[10]	王丹丹, 王学建, 潘南南. CT岛征和黑洞征及其联合征象对原发性脑出血早期血肿扩大的预测价值[J]. 天津医药, 2021, 49(2):199-202.
	WANG D D, WANG X J, PAN N N. The prognostic value of CT island sign,black hole sign and their combined signs for the hematoma enlargement in patients with early stage of primary intracerebral hemorrhage[J]. Tianjin Med J, 2021, 49(2):199-202. doi:10.11958/20200831.
[11]	OLIVEIRA M A L. Surgery for spontaneous intracerebral hemorrhage[J]. Crit Care, 2020, 24(1):45. doi:10.1186/s13054-020-2749-2.
[12]	QIAN S, ZHANG H, DAI H, et al. Is sCD163 a clinical significant prognostic value in cancers? a systematic review and meta-analysis[J]. Front Oncol, 2020, 10:585298. doi:10.3389/fonc.2020.585297.
[13]	BHATTACHARYA A, ASHOURI R, FANGMAN M, et al. Soluble receptors affecting stroke outcomes:potential biomarkers and therapeutic tools[J]. Int J Mol Sci, 2021, 22(3):1108. doi:10.3390/ijms22031108.
[14]	DRIEU A, DU S, STORCK S E, et al. Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid[J]. Nature, 2022, 611(7936):585-593. doi:10.1038/s41586-022-05397-3.
[15]	王靖萱, 陈丹阳, 王佳慧, 等. 血清炎性标志物在脑出血预后评估中的作用研究进展[J]. 神经损伤与功能重建, 2022, 17(12):785-787.
	WANG J X, CHEN D Y, WANG J H, et al. The role of serum inflammatory markers in prognosis evaluation of cerebral hemorrhage[J]. Nerve Injury and Functional Reconstruction, 2022, 17(12):785-787. doi:10.16780/j.cnki.sjssgncj.20220909.
[16]	SILVA-CANDAL A, LOPEZ-DEQUIDT I, RODRIGUEZ-YANEZ M, et al. sTWEAK is a marker of early haematoma growth and leukoaraiosis in intracerebral haemorrhage[J]. Stroke Vasc Neurol, 2021, 6(4):528-535. doi:10.1136/svn-2020-000684.
[17]	DAI J X, CAI J Y, SUN J, et al. Serum soluble tumor necrosis factor-like weak inducer of apoptosis is a potential biomarker for outcome prediction of patients with aneurysmal subarachnoid hemorrhage[J]. Clin Chim Acta, 2020, 510(1):354-359. doi:10.1016/j.cca.2020.07.052.
[18]	刘莹, 王力娜, 崔丽丽, 等. TWEAK,NF-κB在脑梗死大鼠脑组织的表达及氧化苦参碱对其表达的影响[J]. 脑与神经疾病杂志, 2020, 28(3):137-143.
	LIU Y, WANG L N, CUI L L, et al. TWEAK,expression of NF-κB in brain tissue of rats with cerebral infarction and effect of oxymatrine on its expression[J]. Journal of Brain and Neurological Diseases, 2020, 28(3):137-143. doi:CNKI:SUN:LYSJ.0.2020-03-002.
[19]	赵宾, 史肖锦, 钟平. 急性脑梗死患者早期血清肿瘤坏死因子样弱凋亡诱导剂水平与脑白质病变的相关性[J]. 卒中与神经疾病, 2021, 28(1):54-57.
	ZHAO B, SHI X J, ZHONG P. Correlation between serum levels of tumor necrosis factor-like weak apoptosis inducer and white matter lesions in patients with acute cerebral infarction[J]. Stroke and Neurological Diseases, 2021, 28(1):54-57.
[20]	ALTINTAS M S, EYERCI N, KARAYIGIT O, et al. Low sCD163/TWEAK ratio at first day after acute myocardial infarction associated with adverse cardiac remodeling in non-elderly patients[J]. Kardiologiia, 2022, 62(10):49-55. doi:10.18087/cardio.2022.10.n2155.
[21]	MRAK D, ZIERFUSS B, HOBAUS C, et al. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality[J]. Atherosclerosis, 2021, 317(1):41-46. doi:10.1016/j.atherosclerosis.2020.11.026.

组别	n	sCD163/ （μg/L）	sTWEAK/ （ng/L）	sCD163/sTWEAK/ ×10³
对照组	45	56.28±4.12	45.02±3.15	1.25±0.27
病例组	90	310.88±94.78	212.23±77.70	1.50±0.33
t		25.435^＊＊	20.382^＊＊	4.582^＊＊

组别	n	sCD163/ （μg/L）	sTWEAK/ （ng/L）	sCD163/sTWEAK/ ×10³
对照组	45	56.28±4.12	45.02±3.15	1.25±0.27
病例组	90	310.88±94.78	212.23±77.70	1.50±0.33
t		25.435^＊＊	20.382^＊＊	4.582^＊＊

组别	n	sCD163/ （μg/L）	sTWEAK/ （ng/L）	sCD163/sTWEAK/ ×10³
预后良好组	52	274.32±87.87	178.29±74.60	1.34±0.29
预后不良组	38	360.91±80.73	258.67±54.91	1.73±0.25
t		4.777^＊＊	5.619^＊＊	6.581^＊＊

组别	n	sCD163/ （μg/L）	sTWEAK/ （ng/L）	sCD163/sTWEAK/ ×10³
预后良好组	52	274.32±87.87	178.29±74.60	1.34±0.29
预后不良组	38	360.91±80.73	258.67±54.91	1.73±0.25
t		4.777^＊＊	5.619^＊＊	6.581^＊＊

组别	n				男性				年龄/岁			BMI/（kg/m²）							糖尿病
预后良好组	52				26（50.0）				43.52±6.35			23.35±2.47							24（46.2）
预后不良组	38				25（65.8）				43.50±6.19			23.43±2.51							18（47.4）
t或χ²					2.229				0.014			0.133							0.013
组别				冠心病				高血压					幕下出血		发病至手术时间/h
预后良好组				23（44.23）				20（38.46）					15（28.8）		6.12±1.35
预后不良组				20（52.63）				23（60.55）					20（52.6）		6.50±1.47
t或χ²				0.621				4.284^＊					5.227^＊		1.286
组别			手术时间/ min							血肿体积/ mL				TC/ （mmol/L）			TG/ （mmol/L）
预后良好组			116.25±25.84							32.56±3.79				4.67±0.85			4.51±1.47
预后不良组			119.74±26.72							44.85±3.82				5.02±0.89			4.13±1.35
t或χ²			0.623							15.163^＊＊				1.894			1.222
组别		LDL-C/ （mmol/L）				收缩压/ mmHg						舒张压/ mmHg						血糖/ （mmol/L）
预后良好组		2.69±0.56				173.21±10.85						135.79±8.92						6.25±1.58
预后不良组		2.41±0.59				172.05±10.72						134.13±8.76						5.72±1.54
t或χ²		2.272^＊				0.503						0.877						1.561
组别			NIHSS 评分/分				WBC/ （×10⁹/L）				PLT/ （×10⁹/L）					NLR
预后良好组			10.26±3.16				7.35±1.33				183.79±21.14					2.33±0.35
预后不良组			15.10±2.51				9.72±1.75				243.15±33.46					2.76±0.47
t或χ²			7.809^＊＊				7.279^＊＊				10.295^＊＊					4.980^＊＊